EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer

Monika Bar iD, Wiesława Widłak iD, Natalia Vydra iD

International Journal of Cancer · 01.09.2026 · 159 (5) · 1124-1138

DOI: 10.1002/ijc.70522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 04.05.2026. Verfasst von Monika Bar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Drug Resistance, Neoplasm, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Gefördert von: the National Science Center, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer (BC) is the most commonly diagnosed tumor among women worldwide. Approximately 70% of cases are estrogen receptor‐positive (ER+), whose growth is driven by estrogen signaling. Endocrine therapies targeting ER signaling are the common treatment for ER+ disease; however, both intrinsic and acquired endocrine resistance continue to be a major clinical challenge. A growing body of evidence indicates that multiple coregulators influence ER recruitment to its genomic binding sites and tumor growth. Their aberrant expression can promote ligand‐independent ER activation and attenuate the effectiveness of ER‐targeted therapies. Consequently, targeting ERα coregulators has emerged as a promising therapeutic strategy to overcome endocrine resistance. In this review, we synthesize current evidence defining the roles of ERα coregulators in endocrine resistance, critically assess their therapeutic potential, and provide prioritization guidance for clinical development. A deeper understanding of the molecular mechanisms underpinning endocrine resistance is essential to improve treatment outcomes for patients with ER+ BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsEstrogen Receptor alphaDrug Resistance, NeoplasmAntineoplastic Agents, HormonalHumansFemaleSignal TransductionAnimalsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

ERα coregulatorsbreast cancerendocrine resistanceestrogen receptorhormone therapy

Substanzen

Estrogen Receptor alphaAntineoplastic Agents, HormonalESR1 protein, human

Autor:innen und Institutionen

  • Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.

ORCID-Profile: Monika Bar, Wiesława Widłak, Natalia Vydra

Förderung

  • the National Science Center, Poland

Zitieren

APA

Bar, M., Widłak, W., & Vydra, N. (2026). Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer. International Journal of Cancer, 159(5), 1124-1138. https://doi.org/10.1002/ijc.70522

Vancouver

Bar M, Widłak W, Vydra N. Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer. International Journal of Cancer. 2026;159(5):1124-1138. doi:10.1002/ijc.70522

BibTeX
@article{Bar2026,
  author = {Bar, Monika and Widłak, Wiesława and Vydra, Natalia},
  title = {Targeting ERα Coregulator Networks to Overcome Endocrine Resistance in ER + Breast Cancer},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {5},
  pages = {1124--1138},
  doi = {10.1002/ijc.70522}
}
Kostenlos starten →